For example, in a recent large series of breast cancer patients undergoing genetic testing by Ambry Genetics18, 66% of EA patients with pathogenic variants in BRCA1 reported a diagnosis of TNBC, and 30% of EA patients with pathogenic variants in BRCA2 or PALB2 reported a diagnosis of TNBC, both higher frequencies of TNBC than among EA patients in the CBCS. Here, PALB2 is linked to breast carcinoma.